Bupropion Hydrochloride Controlled-release

DRUG3 trials

Sponsors

University of Rochester NCORP Research Base, M.D. Anderson Cancer Center, Thomas Jefferson University

Conditions

Cigarette Smoking-Related CarcinomaHead and Neck Squamous Cell CarcinomaHematopoietic and Lymphatic System NeoplasmLung Non-Small Cell CarcinomaMalignant Solid Neoplasm

Phase 3

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

Active, not recruitingNCT03996265

University of Rochester NCORP Research BaseHematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm

Start: 2019-06-27End: 2026-08-05Target: 422Updated: 2026-01-15

Phase 4

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

RecruitingNCT04604509

M.D. Anderson Cancer CenterCigarette Smoking-Related Carcinoma

Start: 2020-08-04End: 2028-12-31Target: 2010Updated: 2025-10-14

Unknown Phase

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

CompletedNCT04694846

Thomas Jefferson UniversityHead and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma

Start: 2020-08-19End: 2024-08-16Updated: 2025-09-09